Evidence map›Paper›PMID 36951121›Full record

ArticleJournal of cell science2023

Patch repair protects cells from the small pore-forming toxin aerolysin.

Roshan Thapa, Peter A Keyel

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Roshan ThapaDepartment of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0002-0705-906X
Peter A KeyelDepartment of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0001-8637-8538
Texas Tech University · US

Funding

Novel membrane defense systems utilized by the human pathogen LeishmaniaR21AI156225 · NIAID · TEXAS TECH UNIVERSITY · PI KEYEL, PETER A · 2021 to 2022
$405k
American Heart Association-American Stroke Association 16SDG30200001NIAID NIH HHS R21 AI156225NIH HHS 1R21AI156225
6 · The paper itself

Abstract

Aerolysin family pore-forming toxins damage the membrane, but membrane repair responses used to resist them, if any, remain controversial. Four proposed membrane repair mechanisms include toxin removal by caveolar endocytosis, clogging by annexins, microvesicle shedding catalyzed by MEK, and patch repair. Which repair mechanism aerolysin triggers is unknown. Membrane repair requires Ca2+, but it is controversial if Ca2+ flux is triggered by aerolysin. Here, we determined Ca2+ influx and repair mechanisms activated by aerolysin. In contrast to what is seen with cholesterol-dependent cytolysins (CDCs), removal of extracellular Ca2+ protected cells from aerolysin. Aerolysin triggered sustained Ca2+ influx. Intracellular Ca2+ chelation increased cell death, indicating that Ca2+-dependent repair pathways were triggered. Caveolar endocytosis failed to protect cells from aerolysin or CDCs. MEK-dependent repair did not protect against aerolysin. Aerolysin triggered slower annexin A6 membrane recruitment compared to CDCs. In contrast to what is seen with CDCs, expression of the patch repair protein dysferlin protected cells from aerolysin. We propose aerolysin triggers a Ca2+-dependent death mechanism that obscures repair, and the primary repair mechanism used to resist aerolysin is patch repair. We conclude that different classes of bacterial toxins trigger distinct repair mechanisms.

Indexed as

Bacterial ToxinsCalciumMitogen-Activated Protein Kinase KinasesPore Forming Cytotoxic ProteinsaerolysinBacterial ToxinsCalciumMitogen-Activated Protein Kinase KinasesPore Forming Cytotoxic ProteinsAeromonasAnnexinMembrane repairPatch repairPore-forming toxinStreptolysin O

Identifiers

PMID36951121
PMCPMC10198622
OpenAlexW4360600479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.